Panbela Therapeutics Company Description
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs.
The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin.
The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020.
Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Jennifer Simpson |
Contact Details
Address: 712 Vista Boulevard Waconia, Delaware 55387 United States | |
| Phone | 952 479 1196 |
| Website | panbela.com |
Stock Details
| Ticker Symbol | PBLA |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US69833W1071 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D. | Chief Executive Officer, President and Director |
| Susan Horvath | Vice President of Finance, Chief Financial Officer, Secretary and Treasurer |
| Tammy Groene | Vice President of Operations |